RecruitingNCT07117136
Blinatumomab Consolidation in Real World
Real World Outcomes of Blinatumomab Consolidation in Patients With B-cell Acute Lymphoblastic Leukemia
Sponsor
Medical College of Wisconsin
Enrollment
200 participants
Start Date
Aug 28, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- \) aged 18 years or older 2) diagnosed with B-ALL on or after December 1st 2023 3) Not received blinatumomab in an interventional clinical trial setting 4) Willing and able to give informed consent (or retrospective data for deceased patients
Exclusion Criteria1
- N/A
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07117136